LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity

Annals of Clinical and Translational Neurology

Volumn 1, Issue 3, 2014, Pages 199-208

  Liu, Hui Fang ^a   Lu, Song ^a   Ho, Philip Wing Lok ^a   Tse, Ho Man ^a   Pang, Shirley Yin Yu ^a   Kung, Michelle Hiu Wai ^a   Ho, Jessica Wing Man ^a   Ramsden, David B ^b   Zhou, Zhong Jun ^a   Ho, Shu Leong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BECLIN 1; CYTOCHROME C OXIDASE; DOPAMINE TRANSPORTER; LEUCINE RICH REPEAT KINASE 2; RESERPINE; TAU PROTEIN; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE DEPLETION; GENE MUTATION; GENE TARGETING; GENOTYPING TECHNIQUE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; LOCOMOTOR INACTIVITY; MESENCEPHALON; MOUSE; NERVE ENDING; NERVOUS SYSTEM PARAMETERS; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOSOME; UPTAKE ASSAY; WESTERN BLOTTING;

EID: 84928634712     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.45     Document Type: Article

References (40)

1. Mo SJ, Linder J, Forsgren L, et al. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study. Eur J Nucl Med Mol Imaging 2010;37:2154–2164.
2. Sossi V, de la Fuente-Fernandez R, Schulzer M, et al. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007;62:468–474.
3. Sossi V, de la Fuente-Fernandez R, Holden TE, et al. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24:869–876.
4. Bisaglia M, Greggio E, Beltramini M, et al. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies. FASEB J 2013;27:2101–2110.
5. Goldberg MS, Pisani A, Haburcak M, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005;45:489–496.
6. Kitada T, Pisani A, Karouani M, et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin−/− mice. J Neurochem 2009;110:613–621.
7. Cheng F, Vivacqua G, Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat 2011;42:242–248.
8. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445–454.
9. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18:R48–R59.
10. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 2005;365:412–415.
11. Lee BD, Dawson VL, Dawson TM. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci 2012;33:365–373.
12. Marti-Masso JF, Ruiz-Martinez J, Bolano MJ, et al. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord 2009;24:1998–2001.
13. Yue Z, Lachenmayer ML. Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications. Mov Disord 2011;26:1386–1397.
14. Gorostidi A, Ruiz-Martinez, J, Lopez de Munain A, et al. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009;10:157–159.
15. Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol 2011;21:257–265.
16. Mata IF, Wedemeyer WJ, Farrer MJ, et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006;29:286–293.
17. Mandemakers W, Snellinx A, O'Neill MJ, et al. LRRK2 expression is enriched in the striosomal compartment of mouse striatum. Neurobiol Dis 2012;48:582–593.
18. Hehnly H, Stamnes M. Regulating cytoskeleton-based vesicle motility. FEBS Lett 2007;581:2112–2118.
19. Sabo SL, McAllister AK. Mobility and cycling of synaptic protein-containing vesicles in axonal growth cone filopodia. Nat Neurosci 2003;6:1264–1269.
20. Tong Y, Pisani A, Martella G, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009;106:14622–14627.
21. Melrose HL, Dachsel JC, Behrouz B, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010;40:503–517.
22. Zhou H, Huang C, Tong J, et al. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci 2011;7:753–761.
23. Sossi V, de la Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010;25:2717–2723.
24. Zhang X, Yeung PK, McAlonan GM, et al. Transgenic mice over-expressing endothelial endothelin-1 show cognitive deficit with blood-brain barrier breakdown after transient ischemia with long-term reperfusion. Neurobiol Learn Mem 2013;101:46–54.
25. Tieu K, Perier C, Caspersen C, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Investig 2003;112:892–901.
26. Ozerdem U, Wojcik EM, Barkan GA, et al. A practical application of quantitative vascular image analysis in breast pathology. Pathol Res Pract 2013;209:455–458.
27. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671–675.
28. Caudle WM, Richardson JR, Delea KC, et al. Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity. Toxicol Sci 2006;92:490–499.
29. Marazziti D, Mandillo S, Di Pietro C, et al. GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci USA 2007;104:9846–9851.
30. Drenan RM, Grady SR, Steele AD, et al. Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors. J Neurosci 2010;30:9877–9889.
31. Ramonet D, Daher JP, Lin BM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS ONE 2011;6:e18568.
32. Li Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009;12:826–828.
33. Betarbet, R, Sherer, TB, Greenamyre JT. Animal models of Parkinson's disease. BioEssays. 2002;24:308–318.
34. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord 2011;26:993–1002.
35. Metzger RR, Brown JM, Sandoval V, et al. Inhibitory effect of reserpine on dopamine transporter function. Eur J Pharmacol 2002;456:39–43.
36. Berman SB, Zigmond MJ, Hastings TG. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 1996;67:593–600.
37. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010;67:715–725.
38. Bolam JP, Pissadaki EK. Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 2012;27:1478–1483.
39. Schulz-Schaeffer WJ. Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology 2012;79:2298–2299.
40. Adams JR, van Netten, H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005;128(Pt 12):2777–2785.